Epalrestat-RM-28
Epalrestat (EPA), an FDA-approved drug, is a potent inhibitor of aldose reductase and exhibits anticancer activity with poor pharmacokinetic properties. Prodrugs RM-13 and RM-28 are esterase-responsive turn-on fluorogenic prodrugs for the sustained release of EPA to cancer cells
General
Type : Not AlphaBeta Hydrolase target, Pro-Drug, Drug, Fluorescent Probe, Coumarin, Chromen
Chemical_Nomenclature :
Canonical SMILES : C1=C(C=C2C(=C1)C=C(C(O2)=O)COC(CN3C(SC(C3=O)=CC(=CC4=CC=CC=C4)C)=S)=O)OC(C(C)(C)C)=O
InChI : InChI=1S\/C30H27NO7S2\/c1-18(12-19-8-6-5-7-9-19)13-24-26(33)31(29(39)40-24)16-25(32)36-17-21-14-20-10-11-22(15-23(20)38-27(21)34)37-28(35)30(2,3)4\/h5-15H,16-17H2,1-4H3
InChIKey : QVXHYPVMMHQBST-UHFFFAOYSA-N
Other name(s) :
Target
Structures : No structure
Families : No family
References (3)
| Title : Esterase-Responsive Fluorogenic Prodrugs of Aldose Reductase Inhibitor Epalrestat: An Innovative Strategy toward Enhanced Anticancer Activity - Misra_2024_ACS.Appl.Bio.Mater__ |
| Author(s) : Misra R , Barman P , Bhabak KP |
| Ref : ACS Appl Bio Mater , : , 2024 |
| Abstract : |
| PubMedSearch : Misra_2024_ACS.Appl.Bio.Mater__ |
| PubMedID: 39146213 |
| Title : Esterase-Responsive Fluorogenic Prodrugs of Aldose Reductase Inhibitor Epalrestat: An Innovative Strategy toward Enhanced Anticancer Activity - Misra_2024_ACS.Appl.Bio.Mater__ |
| Author(s) : Misra R , Barman P , Bhabak KP |
| Ref : ACS Appl Bio Mater , : , 2024 |
| Abstract : |
| PubMedSearch : Misra_2024_ACS.Appl.Bio.Mater__ |
| PubMedID: 39146213 |
| Title : Esterase-Responsive Fluorogenic Prodrugs of Aldose Reductase Inhibitor Epalrestat: An Innovative Strategy toward Enhanced Anticancer Activity - Misra_2024_ACS.Appl.Bio.Mater__ |
| Author(s) : Misra R , Barman P , Bhabak KP |
| Ref : ACS Appl Bio Mater , : , 2024 |
| Abstract : |
| PubMedSearch : Misra_2024_ACS.Appl.Bio.Mater__ |
| PubMedID: 39146213 |